Literature DB >> 6452195

Hypercalcemia in the accelerated phase of chronic myelogenous leukemia.

R M Walter, B R Greenberg.   

Abstract

Within a recent one-year period, 3 patients in the accelerated phase of chronic myelogenous leukemia were admitted to our medical center with severe hypercalcemia. Simultaneous determinations of ionized calcium and parathyroid hormone levels in 2 of the patients confirmed the hypercalcemia and revealed suppression of parathyroid hormone. We conclude that hypercalcemia in the accelerated phase of chronic myelogeneous leukemia may be more common than previously described and is not mediated by parathyroid hormone. An elevated parathyroid hormone level accompanying hypercalcemia in these patients should suggest the additional diagnosis of primary hyperparathyroidism. Mithramycin was necessary for control in 2 of our cases as well as in others reported in the medical literature and should be an early therapeutic consideration whenever saline diuresis is inadequate.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6452195     DOI: 10.1002/1097-0142(19800901)46:5<1174::aid-cncr2820460516>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Hypercalcemia associated with osteolytic lesions in the extramedullary blastic crisis of chronic myelogenous leukemia: report of a case.

Authors:  K Kubota; T Yanagisawa; H Kurabayashi; K Ono; T Shirakura; K Nagashima; H Yatabe; Y Nakazato
Journal:  Blut       Date:  1989-11

2.  Hypercalcaemia with radiographic abnormalities in chronic myeloid leukaemia.

Authors:  N Sharma; S Jain; S Kumari; S Varma
Journal:  Postgrad Med J       Date:  1998-05       Impact factor: 2.401

3.  Artefactual serum hyperkalaemia and hypercalcaemia in essential thrombocythaemia.

Authors:  M R Howard; S Ashwell; L R Bond; I Holbrook
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

Review 4.  Bone biopsy in haematological disorders.

Authors:  R Burkhardt; B Frisch; R Bartl
Journal:  J Clin Pathol       Date:  1982-03       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.